User login
Treating pneumonia with azithromycin is linked to lower risk of death but a slightly higher risk of myocardial infarction in older patients, according to a large retrospective cohort study.
Although azithromycin is recommended in combination with macrolides for the first-line treatment of patients hospitalized with pneumonia, recent research suggests that azithromycin is associated with an increased risk of cardiovascular events.
However, the current findings suggest that although the drug is associated with a slight increase in the risk of myocardial infarction (number needed to harm equals 144), it is not associated with "any cardiac event," cardiac arrhythmia, or heart failure, and that the reduction in 90-day mortality risk (number needed to treat of 21) is large enough to provide an overall net benefit.
Dr. Eric M. Mortensen of the Veterans Affairs North Texas Health Care system, Dallas, and his colleagues reported their findings on treating pneumonia with azithromycin in JAMA.
In the current study, 90-day mortality in 31,863 patients aged 65 years and older who were exposed to azithromycin was significantly lower than in an equal number of propensity-matched controls who were not exposed (17.4% vs. 22.3%; odds ratio, 0.73).
The risk of myocardial infarction, however, was significantly increased in the azithromycin group (5.1% vs. 4.4%; OR, 1.17), the investigators reported.
Azithromycin use was defined as patients’ receipt of at least one dose of azithromycin during the first 48 hours after admission.
Study subjects were a mean age of 77.8 years in the national Department of Veterans Affairs administrative database who were hospitalized with pneumonia between 2002 and 2012 (JAMA 2014 June 4 [doi: 10.1001/jama.2014.4304]). Most patients (98%) were male.
The study hada relativelysmall number of few female subjects and relied "upon ICD-9 diagnosis of cardiovascular events rather than clinical information, which particularly may affect the diagnosis of heart failure." However, researchers said, treating physicians were likely to have believed that the patients in the study indeed had pneumonia and did not show any bias toward azithromycin.
Dr. W. Michael Alberts, FCCP, comments: Azithromycin is a widely used (perhaps too widely) and effective (it’s hard to be too effective) antibiotic commonly used in patients with respiratory illnesses. Recent reports, however, have called the safety of this medication into question. The results of this very large study may ease the practitioner’s anxiety, at least when treating patients hospitalized with pneumonia.
For a slight increased risk of heart attack, use of azithromycin provides a significantly lower risk of death. As long as the drug is used for the appropriate indication, I’ll take that deal in most situations.
Dr. W. Michael Alberts, FCCP, comments: Azithromycin is a widely used (perhaps too widely) and effective (it’s hard to be too effective) antibiotic commonly used in patients with respiratory illnesses. Recent reports, however, have called the safety of this medication into question. The results of this very large study may ease the practitioner’s anxiety, at least when treating patients hospitalized with pneumonia.
For a slight increased risk of heart attack, use of azithromycin provides a significantly lower risk of death. As long as the drug is used for the appropriate indication, I’ll take that deal in most situations.
Dr. W. Michael Alberts, FCCP, comments: Azithromycin is a widely used (perhaps too widely) and effective (it’s hard to be too effective) antibiotic commonly used in patients with respiratory illnesses. Recent reports, however, have called the safety of this medication into question. The results of this very large study may ease the practitioner’s anxiety, at least when treating patients hospitalized with pneumonia.
For a slight increased risk of heart attack, use of azithromycin provides a significantly lower risk of death. As long as the drug is used for the appropriate indication, I’ll take that deal in most situations.
Treating pneumonia with azithromycin is linked to lower risk of death but a slightly higher risk of myocardial infarction in older patients, according to a large retrospective cohort study.
Although azithromycin is recommended in combination with macrolides for the first-line treatment of patients hospitalized with pneumonia, recent research suggests that azithromycin is associated with an increased risk of cardiovascular events.
However, the current findings suggest that although the drug is associated with a slight increase in the risk of myocardial infarction (number needed to harm equals 144), it is not associated with "any cardiac event," cardiac arrhythmia, or heart failure, and that the reduction in 90-day mortality risk (number needed to treat of 21) is large enough to provide an overall net benefit.
Dr. Eric M. Mortensen of the Veterans Affairs North Texas Health Care system, Dallas, and his colleagues reported their findings on treating pneumonia with azithromycin in JAMA.
In the current study, 90-day mortality in 31,863 patients aged 65 years and older who were exposed to azithromycin was significantly lower than in an equal number of propensity-matched controls who were not exposed (17.4% vs. 22.3%; odds ratio, 0.73).
The risk of myocardial infarction, however, was significantly increased in the azithromycin group (5.1% vs. 4.4%; OR, 1.17), the investigators reported.
Azithromycin use was defined as patients’ receipt of at least one dose of azithromycin during the first 48 hours after admission.
Study subjects were a mean age of 77.8 years in the national Department of Veterans Affairs administrative database who were hospitalized with pneumonia between 2002 and 2012 (JAMA 2014 June 4 [doi: 10.1001/jama.2014.4304]). Most patients (98%) were male.
The study hada relativelysmall number of few female subjects and relied "upon ICD-9 diagnosis of cardiovascular events rather than clinical information, which particularly may affect the diagnosis of heart failure." However, researchers said, treating physicians were likely to have believed that the patients in the study indeed had pneumonia and did not show any bias toward azithromycin.
Treating pneumonia with azithromycin is linked to lower risk of death but a slightly higher risk of myocardial infarction in older patients, according to a large retrospective cohort study.
Although azithromycin is recommended in combination with macrolides for the first-line treatment of patients hospitalized with pneumonia, recent research suggests that azithromycin is associated with an increased risk of cardiovascular events.
However, the current findings suggest that although the drug is associated with a slight increase in the risk of myocardial infarction (number needed to harm equals 144), it is not associated with "any cardiac event," cardiac arrhythmia, or heart failure, and that the reduction in 90-day mortality risk (number needed to treat of 21) is large enough to provide an overall net benefit.
Dr. Eric M. Mortensen of the Veterans Affairs North Texas Health Care system, Dallas, and his colleagues reported their findings on treating pneumonia with azithromycin in JAMA.
In the current study, 90-day mortality in 31,863 patients aged 65 years and older who were exposed to azithromycin was significantly lower than in an equal number of propensity-matched controls who were not exposed (17.4% vs. 22.3%; odds ratio, 0.73).
The risk of myocardial infarction, however, was significantly increased in the azithromycin group (5.1% vs. 4.4%; OR, 1.17), the investigators reported.
Azithromycin use was defined as patients’ receipt of at least one dose of azithromycin during the first 48 hours after admission.
Study subjects were a mean age of 77.8 years in the national Department of Veterans Affairs administrative database who were hospitalized with pneumonia between 2002 and 2012 (JAMA 2014 June 4 [doi: 10.1001/jama.2014.4304]). Most patients (98%) were male.
The study hada relativelysmall number of few female subjects and relied "upon ICD-9 diagnosis of cardiovascular events rather than clinical information, which particularly may affect the diagnosis of heart failure." However, researchers said, treating physicians were likely to have believed that the patients in the study indeed had pneumonia and did not show any bias toward azithromycin.
Key clinical point: The benefit of azithromycin for elderly pneumonia patients outweighs MI risk.
Major finding: Ninety-day mortality in patients receiving azithromycin was 17.4% vs. 22.3% among controls.
Data source: A retrospective cohort study of 63,726 adults aged 65 years or older and hospitalized for pneumonia.
Disclosures: Support came from a National Institute of Nursing Research grant. Dr. Mortensen had no disclosures. Other researchers received grants from industry sources.
